56F.F EXACT THERAP. AS NK 0004

Healthcare Biotechnology Frankfurt Exchange
0.0100 EUR
Close of Nov 11, 2026
0.0100 0.1980
Market cap
EUR 1.12M
P/E
-
P/B
0.18x
ROE
-283.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 56F.F undervalued?

Graham number

The Graham number of EXACT THERAP. AS NK 0004 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

EXACT THERAP. AS NK 0004 fundamental analysis

No fundamental analysis for EXACT THERAP. AS NK 0004 yet.

EXACT THERAP. AS NK 0004 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About EXACT THERAP. AS NK 0004

EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway. The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various applications, including oncology, neurological conditions, and gene therapy. The company's ACT platform…

Full company profile